1 / 6

NCCR IP9 WORKSHOP 17 th May 2006 Patentability of Life Forms By Michelangelo Temmerman

NCCR IP9 WORKSHOP 17 th May 2006 Patentability of Life Forms By Michelangelo Temmerman. IP9 Workshop. Patenting Gene Sequences. Unmodified gene (nucleic) sequences: discovery or invention?

remedy
Download Presentation

NCCR IP9 WORKSHOP 17 th May 2006 Patentability of Life Forms By Michelangelo Temmerman

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. NCCR IP9 WORKSHOP 17th May 2006 Patentability of Life Forms By Michelangelo Temmerman

  2. IP9 Workshop

  3. Patenting Gene Sequences • Unmodified gene (nucleic) sequences: discovery or invention? • Patenting higher life forms (US/Europe) or their building blocks: gene sequences and cells (Canada)? • Role of the industrial application requirement (purpose bound protection?) • The inventiveness of a sequence isolated by a known process • Equation between gene sequences and chemical compounds

  4. Dual Protection UPOV/Patents • Excluding plant varieties from patentability (Europe) or allowing dual protection (US/Australia)? • Is the European approach efficiently excluding varieties? (loopholes?) • Is the UPOV system still needed? • What about the exclusion of animal breeds?

  5. Need for International Harmonization • International patent law harmonization: pros & cons • Should we leave the sensitive area of biotechnology up to regional/national authorities? • Special treatment for developing countries?

  6. Ordre Public and Morality in the Patent Office • Is the patent office the right place to deal with those concepts? (taking into account its limited role in the regulatory framework and its practical limitations to assess risks) • Concept of ordre public (generally and for biotechnology in specific) • Concept of morality (generally and for biotechnology in specific) • Human rights

More Related